Author: TreatSMA
TreatSMA met with the Roche UK team
On Monday 24 September, TreatSMA held a meeting with Roche UK to discuss our advocacy work and the company’s plans related to risdiplam.
Our condition costs millions, our lives are priceless. Treat SMA!
Today is SMA Awareness Day.
An SMA gene therapy trial starting in London
The first European trial of AVXS-101, an experimental genetic therapy for spinal muscular atrophy, has opened in London.
Registration open for next NICE Committee meeting on Spinraza
Registration is now open for the NICE meeting on Spinraza which will be held at NICE Manchester office on Tuesday 23 October 2018.
At a Spinraza meeting at NICE today
Today we kept pushing for wide access to treatment at a closed-door meeting at NICE.
Prime Minister asked about Spinraza
Mary Glindon MP asked the Prime Minister about problems with access to Spinraza.
TreatSMA advocates for universal newborn screening for SMA
TreatSMA submits an opinion on universal newborn screening for SMA.
TreatSMA has responded to draft nusinersen guidance
TreatSMAS has submitted its comments to the draft NICE guidance on nusinersen.